TL;DR: Eugit Therapeutics is a Y Combinator Summer 2022 startup Enabling Tissue Targeting of Therapies, currently active with a team of 2.
Enabling Tissue Targeting of Therapies
Last verified:
Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator (S22).
Built by LemStudio
Yes. Eugit Therapeutics was funded by Y Combinator in the Summer 2022 batch. Enabling Tissue Targeting of Therapies
Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on t…
Eugit Therapeutics was part of Y Combinator's Summer 2022 batch.
Eugit Therapeutics has a team of 2 people according to Y Combinator's directory.
Eugit Therapeutics is currently listed as Active with a team of 2 in Y Combinator's directory.
Loading interactive view…